Jefferies Financial Group Inc. purchased a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 30,685 shares of the biopharmaceutical company’s stock, valued at approximately $1,020,000.
Other hedge funds also recently made changes to their positions in the company. Lido Advisors LLC purchased a new stake in Agios Pharmaceuticals during the 3rd quarter worth about $411,000. Fulcrum Asset Management LLP bought a new position in Agios Pharmaceuticals in the 3rd quarter worth about $94,000. AlphaCentric Advisors LLC boosted its stake in Agios Pharmaceuticals by 3.9% in the 3rd quarter. AlphaCentric Advisors LLC now owns 14,731 shares of the biopharmaceutical company’s stock worth $490,000 after purchasing an additional 558 shares during the period. Alps Advisors Inc. grew its holdings in Agios Pharmaceuticals by 31.7% during the 3rd quarter. Alps Advisors Inc. now owns 79,081 shares of the biopharmaceutical company’s stock valued at $2,629,000 after buying an additional 19,022 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Agios Pharmaceuticals during the 3rd quarter valued at about $101,000.
Agios Pharmaceuticals Stock Down 0.5%
Shares of AGIO stock traded down $0.17 on Friday, reaching $31.59. The company’s stock had a trading volume of 371,334 shares, compared to its average volume of 1,271,474. Agios Pharmaceuticals, Inc. has a 12-month low of $22.24 and a 12-month high of $46.00. The company has a market capitalization of $1.89 billion, a P/E ratio of -5.00 and a beta of 0.66. The stock’s 50 day simple moving average is $33.09 and its 200-day simple moving average is $31.85.
Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.24) by $0.15. Agios Pharmaceuticals had a negative return on equity of 34.63% and a negative net margin of 264.76%. The company had revenue of $55.39 million during the quarter, compared to analyst estimates of $51.65 million. Research analysts expect that Agios Pharmaceuticals, Inc. will post -5.72 EPS for the current year.
Analyst Upgrades and Downgrades
AGIO has been the topic of several analyst reports. Bank of America upped their price target on Agios Pharmaceuticals from $46.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, September 21st. Weiss Ratings lowered shares of Agios Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, November 9th. JPMorgan Chase & Co. raised their price objective on shares of Agios Pharmaceuticals from $31.00 to $34.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. Citigroup boosted their price objective on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Finally, HC Wainwright upped their target price on shares of Agios Pharmaceuticals from $55.00 to $62.00 and gave the stock a “buy” rating in a report on Friday, November 6th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $42.12.
View Our Latest Report on AGIO
Insider Buying and Selling at Agios Pharmaceuticals
In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 7,866 shares of the firm’s stock in a transaction dated Monday, October 26th. The stock was sold at an average price of $37.69, for a total value of $296,469.54. Following the sale, the insider owned 54,645 shares of the company’s stock, valued at $2,059,570.05. This trade represents a 12.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 9,855 shares of company stock valued at $371,112. Company insiders own 5.40% of the company’s stock.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals is a biopharmaceutical company focused on developing medicines for rare genetic diseases, particularly blood disorders. Based in Cambridge, Massachusetts, the company applies research into cellular metabolism to identify potential treatments. Its marketed medicine, PYRUKYND (mitapivat), is approved in the United States to treat adults with pyruvate kinase deficiency, a rare inherited disorder that can cause anemia. Agios also develops therapies for other rare diseases, including additional blood disorders.
Featured Stories
- Five stocks we like better than Agios Pharmaceuticals
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report).
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
